Q-omics provides the consensus-scored MIR202HG profile across patient tissues and cancer cell-line models. MIR202HG expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR202HG is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, MIR202HG RNA expression shows 8,554 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, BLCA, and ACC as cancer lineages where MIR202HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR202HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR202HG survival associations across molecular data types. MIR202HG RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR202HG RNA expression–survival associations across cancer types. High MIR202HG expression shows unfavorable associations in UVM, READ, ACC and UCS, but favorable associations in BRCA and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR202HG RNA expression.
This table summarizes MIR202HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR202HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR202HG shows lower tumor expression in BLCA, BRCA, LUAD, LUSC and STAD and higher tumor expression in HNSC. The BLCA box plot shows higher MIR202HG RNA expression in normal versus tumor tissue (log2 FC = −0.301, t-test p < 0.001).
This table shows molecular features associated with MIR202HG in patient tissues and cancer cell lines. In patient samples, MIR202HG shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
